Implantable probe device and preparation method thereof, electrode device and electronic equipment

The invention provides an implantable probe device and a preparation method thereof, an electrode device and electronic equipment. The implantable probe device includes: a flexible substrate including a first portion and a plurality of second portions separated from each other; a probe pad array including a plurality of contact pads, the plurality of contact pads being formed in the first portion; a plurality of electrodes formed in respective end sections of the plurality of second portions away from the first portion; a plurality of leads formed in the plurality of second portions to electrically connect the plurality of electrodes to the corresponding contact pads, respectively; each second part in the plurality of second parts comprises N stages of segments, the Nth stage of segment in the plurality of second parts comprises each tail end segment of the plurality of second parts, and a plurality of branches are branched from each segment in the nth stage of segment as the (n + 1) th stage of segment, and the leads formed in each of the (n + 1) th stage of segments are a subset of the leads formed in the nth stage of segments, 0 < n < N.

The abstract as published by the patent office, from US20250366759A1. It describes the invention; it is not a statement of what is protected.

• Interface and electrodes

  Electrodes and arrays

What the filing appears to be about, read by published rules from its title, abstract and classification codes (A61B2562/046, A61B2562/125, A61B2562/164, A61B5/24, A61B5/263). The claims define what a patent protects, and they are not read here.

Interface and electrodes

Everything downstream works with what the contacts pick up. Their number, size and distance from the neurons set the ceiling on the signal. The problem behind it: more contacts, closer to neurons, that still record after years in tissue that reacts to them.

Why the layer matters to the field, not a judgement of this filing. A patent family shows that protection was sought. It does not show that the technology was built, is used in a product, or works in people. The whole stack

One invention, published 4 times in 3 offices. Each publication opens in Espacenet.

• ChinaCN115363592A22 Nov 2022CN115363592B12 Dec 2023 · grant
• International (PCT)a route to several countries, not a countryWO2024046185A17 Mar 2024
• United StatesUS20250366759A14 Dec 2025

1. 31 Aug 2022First filingEarliest priority, at China. The family is counted in this year.
2. 22 Nov 2022First publicationCN115363592A, China.
3. 23 Aug 2023ApplicationsFiled at International (PCT), United States.
4. 12 Dec 2023Grant publishedCN115363592B, China.
5. 28 Feb 2025Owner recordedUnited States, on US20250366759A1: assignment; owner named: NEUROXESS TECHNOLOGY (SHANGHAI) CO., LTD., CHINA.
6. 24 Dec 2025Office recordInternational (PCT), on WO2024046185A1: ep: pct application non-entry in european phase.

Dates as the offices published them. Office records are in the offices' own words and are a selection: refusals, lapses and withdrawals, and records that name an owner. Each concerns one member of the family, not the family as a whole, and another member in the same office may stand. Whether a patent is in force today is not assessed.

Organisation

NeuroXess · 65 families identified

• Bibliographic data, family members and office records: European Patent Office, Open Patent Services (the DOCDB and INPADOC databases), read 7 Oct 2026.
• The record itself, with its claims and description: US20250366759A1 in Espacenet
• Counted as a BCI patent family: classified G06F3/015, without a brain signal in the text; filed by 上海脑虎科技有限公司, an organisation already in the graph; a hardware layer of the stack, filed by a company that builds interfaces. How families are found and judged